Emerald Health Therapeutics (TSX-Venture: EMH) isn’t letting the grass grow under its feet.
The Vancouver-based company has entered into a binding term sheet with a single Canadian institutional accredited investor who is set to purchase 2,500 secured convertible debenture units of the Company at a price of $10,000 per Convertible Debenture Unit for gross proceeds of $25,000,000.
Each Convertible Debenture Unit is comprised of one 5.0% secured convertible debenture of the Company in the principal amount of $10,000 and 5,000 common share purchases warrants of the Company. The closing date of the offering is scheduled to be on or about next Wednesday, Sept. 4
Shares hiked nine cents, or 5.1%, to $1.85, on 390,000 shares
